BioStock: Strong signals from Saniona in rare disease

This week, biotechnology company Saniona was able to communicate positive topline results from the open label extension of the phase II study with Tesomet in hypothalamic obesity. This is encouraging news ahead of the upcoming supportive phase IIb study that the FDA has called for. Yesterday, the company held a webcast where the results – which show statistically significant and clinically meaningful reductions in body weight and waist circumference as well as improved glycemic control – were presented. 

Read the full article about Saniona at biostock.se:

https://www.biostock.se/en/strong-signals-from-saniona-in-rare-disease/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se